Last reviewed · How we verify
VYD222 (pemivibart)
VYD222 (pemivibart) is an investigational antiviral medication that works by inhibiting the replication of SARS-CoV-2.
VYD222 (pemivibart) is an investigational antiviral medication that works by inhibiting the replication of SARS-CoV-2. Used for Treatment of mild to moderate COVID-19.
At a glance
| Generic name | VYD222 (pemivibart) |
|---|---|
| Sponsor | Invivyd, Inc. |
| Drug class | Antiviral |
| Target | SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), preventing the virus from replicating. This mechanism of action is similar to other antiviral medications that target the RdRp enzyme.
Approved indications
- Treatment of mild to moderate COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VYD222 (pemivibart) CI brief — competitive landscape report
- VYD222 (pemivibart) updates RSS · CI watch RSS
- Invivyd, Inc. portfolio CI